ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXO · Real-Time Price · USD
2.060
-0.040 (-1.90%)
At close: Aug 10, 2026, 4:00 PM EDT
2.055
-0.005 (-0.24%)
After-hours: Aug 10, 2026, 7:34 PM EDT
ALX Oncology Holdings Employees
ALX Oncology Holdings had 43 employees as of March 31, 2026. The number of employees decreased by 22 or -33.85% compared to the same quarter last year.
Employees
43
Change
-22
Growth
-33.85%
Revenue / Employee
n/a
Profits / Employee
-$1,881,163
Market Cap
284.85M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 43 | -22 | -33.85% |
| Dec 31, 2025 | 43 | -37 | -46.25% |
| Sep 30, 2025 | 44 | -45 | -50.56% |
| Jun 30, 2025 | 49 | -32 | -39.51% |
| Mar 31, 2025 | 65 | -9 | -12.16% |
| Dec 31, 2024 | 80 | 8 | 11.11% |
| Sep 30, 2024 | 89 | 18 | 25.35% |
| Jun 30, 2024 | 81 | 9 | 12.50% |
| Mar 31, 2024 | 74 | 9 | 13.85% |
| Dec 31, 2023 | 72 | 14 | 24.14% |
| Sep 30, 2023 | 71 | 16 | 29.09% |
| Jun 30, 2023 | 72 | 20 | 38.46% |
| Mar 31, 2023 | 65 | 21 | 47.73% |
| Dec 31, 2022 | 58 | 15 | 34.88% |
| Sep 30, 2022 | 55 | 23 | 71.88% |
| Jun 30, 2022 | 52 | 23 | 79.31% |
| Mar 31, 2022 | 44 | 20 | 83.33% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 288 |
| Zentalis Pharmaceuticals | 106 |
| Neumora Therapeutics | 92 |
| Lineage Cell Therapeutics | 77 |
| InflaRx | 65 |
| Immuneering | 57 |
| Surrozen | 44 |
| Eledon Pharmaceuticals | 33 |
ALXO News
- 4 days ago - ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 days ago - ALX Oncology Holdings Earnings release: Q2 2026 - Filings
- 4 days ago - ALX Oncology Holdings Quarterly report: Q2 2026 - Filings
- 5 weeks ago - ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules - GlobeNewsWire
- 5 weeks ago - ALX Oncology chairman Corey Goodman steps down, Scott Garland succeeds - TheFly
- 5 weeks ago - ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel - GlobeNewsWire
- 2 months ago - ALX Oncology Holdings Transcript: AGM 2026 - Transcripts
- 2 months ago - ALX Oncology Holdings Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts